standard-dose methylprednisolone/prednisone.
Phase 3
standard-dose methylprednisolone/prednisone. is one of 5 therapeutic programs targeting ITP - Immune Thrombocytopenia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in ITP - Immune Thrombocytopenia
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Darzalex
Johnson & JohnsonApproved
Olumiant
Eli LillyPhase 2
standard-dose methylprednisolone/prednisone.
IInstitute of Hematology & Blood Diseases Hospital, China
Phase 3
TPO-RA
IInstitute of Hematology & Blood Diseases Hospital, China
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ITP - Immune Thrombocytopenia1 trial
Efficacy and Safety of Multi-Target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia: A Prospective, Single-arm, Multicenter, Exploratory Trial
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Approved·NCT07788456·38 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]